Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector

A method of treating or slowing the progression of a solid tumor that expresses PD-L1, the method comprising screening the subject for an HLA:

• A*02 haplotype and treating the subject that is positive for the HLA:
• A*02 haplotype with a PD-L1 binding molecule comprising a polypeptide having the sequence of SEQ ID NO:
• 1;
• wherein the PD-L1 binding molecule is administered at a dose in the range of about 50 μg/kg, about 63 μg/kg, about 75 μg/kg, about 80 μg/kg, or about 85 μg/kg of the subject's body weight.

A method of treating or slowing the progression of a solid tumor, wherein the method comprises administering to a subject in need thereof an effective amount of a PD-L1 binding molecule, wherein the PD-L1 binding molecule comprises a polypeptide having the sequence of SEQ ID NO:

• 1;
• wherein the PD-L1 binding molecule is administered at a dose in the range of about 50 μg/kg, about 63 μg/kg, about 75 μg/kg, about 80 μg/kg, or about 85 μg/kg of the subject's body weight;
• and/or
• wherein prior to administration of the PD-L1 binding molecule, PD-L1 expression is detected on cells isolated or derived from the solid tumor;
• and/or
• wherein prior to administration of the PD-L1 binding molecule, the subject is screened for an HLA:
• A*02 haplotype.

A method of treating or slowing the progression of a solid tumor, wherein the method comprises administering to a subject in need thereof an effective amount of a PD-L1 binding molecule, wherein the PD-L1 binding molecule comprises a polypeptide having the sequence of SEQ ID NO:

• 1;
• wherein the PD-L1 binding molecule is administered at a dose in the range of about 50 μg/kg, about 63 μg/kg, about 75 μg/kg, about 80 μg/kg, or about 85 μg/kg of the subject's body weight;
• and
• wherein prior to administration of the PD-L1 binding molecule, PD-L1 expression is detected on cells isolated or derived from the solid tumor.

A method of treating or slowing the progression of a solid tumor, wherein the method comprises administering to a subject in need thereof an effective amount of a PD-L1 binding molecule, wherein the PD-L1 binding molecule comprises a polypeptide having the sequence of SEQ ID NO:

• 1;
• wherein the PD-L1 binding molecule is administered at a dose in the range of about 50 μg/kg, about 63 μg/kg, about 75 μg/kg, about 80 μg/kg, or about 85 μg/kg 1 μg/kg to about 200 #g/kg of the subject's body weight;
• and
• wherein prior to administration of the PD-L1 binding molecule, the subject is screened for CMV.